Total revenue for the fourth quarter and full year 2025 was approximately $72M and $277M, representing an increase of 51% and 55%, respectively, over the corresponding periods in 2024. Cash, cash equivalents and marketable securities were approximately $227M as of December 31, 2025. “2025 was a pivotal year for Adaptive, marked by accelerating momentum across our MRD business driven by strong growth in clonoSEQ adoption,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies (ADPT). “As we look ahead to 2026, we are well-positioned to extend our leadership in MRD testing, sustain strong clonoSEQ volume and ASP growth, and further expand MRD profitability.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies price target raised to $20 from $19 at TD Cowen
- Adaptive Biotechnologies subsidiary completes key Series A financing
- Adaptive Biotechnologies: Strategic Collaborations and Growth Potential Drive Buy Rating
- Adaptive Biotechnologies enters two licensing agreements with Pfizer
- Cathie Wood Capitalizes the Surge in Iridium and Biotech Stocks